Status: Recruiting
GenSci145 as Monotherapy or in Combination Therapy, in Participants With PIK3CA-mutated, Locally Advanced or Metastatic Solid Tumors.
An international, multicenter, open-label, Phase 1/2 clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of GenSci145, as monotherapy or in combination therapy, in participants with PIK3CA-mutated, locally advanced or metastatic solid tumors.
Participants needed: 186
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Changchun GeneScience Pharmaceutical Co., Ltd.Updated: May 27, 2026Locations: 1
Eligibility criteria
Ability to understand and voluntarily provide written ICF. [+30]
History of any active malignancy within ≤2 years prior to the first dose of GenS... [+33]